Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
High-Risk Cutaneous Squamous Cell Carcinoma: Staging, Imaging, and Adjuvant Treatment
Description
The talk focused on managing high-risk cutaneous squamous cell carcinoma, emphasizing that dermatologists and Mohs surgeons must think beyond reconstruction and consider staging, imaging, and adjuvant treatment. The speaker highlighted clinical red flags such as immunosuppression, rapidly growing or recurrent tumors, lesions on high-risk sites like the ears, lips, genitalia, neck, and preauricular area, poorly differentiated tumors, perineural invasion, lymphovascular invasion, and tumors arising in previously radiated or inflamed skin. Existing staging systems like AJCC and Brigham and Women’s were described as useful but incomplete, especially for patients with minor risk factors, transplant recipients, or other immunosuppressed patients who may be understaged. Imaging, usually CT of the head and neck, was recommended for patients with bony invasion or higher-risk disease, particularly T2B, T2A-high, and T3 tumors, because imaging can change management and sometimes redirect patients to head and neck oncology. Sentinel lymph node biopsy was discussed as a consideration in select high-risk cases, especially T2B and T3 lesions, although it is not commonly used for SCC. The speaker also reviewed newer tools such as risk models, transplant-specific classification systems, and gene expression profiling, suggesting these may help when standard staging does not fully capture prognosis or when treatment decisions are uncertain. Overall, surgery remains central, but high-risk patients may also need imaging, radiation, lymph node evaluation, medical oncology input, or immunotherapy.
View moreConclusions
- Current staging systems such as AJCC8 and BWH are useful, but they miss a meaningful subset of high-risk cutaneous squamous cell carcinomas and should be supplemented by additional clinical and pathologic factors.
- Tumor behavior is driven not just by size, but also by features like immunosuppression, rapid growth, poorly defined borders, prior radiation or inflammation, poor differentiation, perineural invasion, lymphovascular invasion, and depth of invasion.
- Even small or seemingly low-stage SCCs can behave aggressively, especially when minor risk factors are present or when the patient is immunosuppressed.
- High-risk locations such as the ear, lip, genitalia, neck, and scar sites are associated with worse outcomes and deserve extra caution.
- Radiologic imaging is valuable for selected high-risk SCCs, especially for suspected bony or orbital invasion, perineural spread, nodal disease, recurrent tumors, and higher-stage lesions.
- Imaging can uncover subclinical disease and change management substantially, including prompting referral to head and neck oncology or altering the surgical plan.
- Sentinel lymph node biopsy should be considered in selected high-risk cases, particularly BWH T2b and T3 tumors, because nodal positivity is not rare in this group.
- Many poor outcomes and deaths from SCC appear to come from uncontrolled local-regional disease rather than distant metastasis alone.
- Recurrent SCCs and tumors with satellitosis or in-transit metastasis have particularly poor prognoses and require aggressive multidisciplinary management.
- Gene expression profiling can add prognostic information beyond traditional staging and may help identify patients who need imaging, radiation, or closer surveillance.
- Risk models and GEP tests appear most helpful when standard staging leaves uncertainty or when patient preferences make treatment decisions less straightforward.
- For some high-risk SCCs, surgery alone is insufficient, and adjuvant radiation, nodal staging, or immunotherapy may be needed to optimize outcomes.
- Validation of Current Staging Systems in HNCSCC: A Multinational Cohort Study.
- Identifying the impact of minor risk factors in Brigham and Women’s Hospital stage T1 cutaneous squamous cell carcinomas on risk of poor outcomes: A retrospective cohort study.#10.1016/j.jaad.2025.02.052
- Lymphovascular invasion is an independent predictor of metastasis and disease-specific death in cutaneous squamous cell carcinoma: A multicenter retrospective study.#10.1016/j.jaad.2025.04.029
- Satellitosis/in-transit metastasis in cutaneous squamous cell carcinoma: Risk factors and the prognostic significance.#10.1001/jamadermatol.2022.0001
- The role of imaging in the management of patients with nonmelanoma skin cancer: When is imaging necessary?#10.1016/j.jaad.2015.10.009
- Detection of subclinical disease with baseline and surveillance imaging in high-risk cutaneous squamous cell carcinomas.#10.1016/j.jaad.2019.10.067
- Perioperative imaging for high-stage cutaneous squamous cell carcinoma helps guide management in nearly a third of cases: A single-institution retrospective cohort. J Am Acad Dermatol. 2023 May;88(5):1209-1211. doi: 10.1016/j.jaad.2023.01.012.#10.1016/j.jaad.2023.01.012
- Radiologic imaging aids management of high-risk cutaneous squamous cell carcinoma: A retrospective cohort study.#10.1016/j.jaad.2025.04.028
- Staging for cutaneous squamous cell carcinoma as a predictor of sentinel lymph node biopsy results: meta-analysis of American Joint Committee on Cancer criteria and a proposed alternative system.#10.3410/f.718234424.793489535
- SLNB in cutaneous SCC: A review of the current state of literature and the direction for the future.#10.1016/j.jaad.2017.04.922
- Nodal staging of high-risk cutaneous squamous cell carcinoma.
- Rates of Upstaging, Between Diagnosis and Surgery, and Clinical Management of Metastatic Cutaneous Squamous Cell Carcinoma: A Case-Control Study.#10.1097/dss.0000000000003224
- Outcomes of Sentinel Lymph Node Biopsy for Primary Cutaneous Squamous Cell Carcinoma of the Head and Neck.#10.1177/0194599813496044a159
- riSCC: A personalized risk model for the development of poor outcomes in cutaneous squamous cell carcinoma.#10.1007/978-3-662-47081-7_1
- EADO classification of difficult-to-treat cutaneous squamous cell carcinoma in transplant recipients.#10.1111/jdv.70317
- Risk of recurrence, metastasis, and death for cutaneous squamous cell carcinomas with solitary large caliber perineural invasion: A multicenter cohort study.#10.1016/j.jaad.2025.10.054
- Patterns of disease-specific death from cutaneous squamous cell carcinoma: A multicenter retrospective cohort.
- Recurrent status is associated with poor outcomes in cutaneous squamous cell carcinoma.#10.1007/978-3-662-47081-7_1
- Gene expression profiling for metastatic risk in head and neck cutaneous squamous cell carcinoma.#10.58837/chula.the.2000.255
- Commentary on 'Clinical Versus Histologic Margins for Cutaneous Squamous Cell Carcinoma: Comparing Outcomes for High-Risk Tumors Treated With Mohs Micrographic Surgery.'#10.1097/dss.0000000000004324
- Integrating 40-GEP Testing to Improve Clinical Recommendations for Adjuvant Radiation for Cutaneous Squamous Cell Carcinoma: Multidisciplinary Consensus Guidelines.
- Gene Expression Profiling (GEP) in Dermatology, Part 1: Introduction, Development, Benefits, Limitations, and Future Directions of GEP.#10.1016/j.jaad.2025.10.084
- Gene Expression Profiling (GEP) in Dermatology, Part 2: Clinical Applications of GEP in Dermatology.#10.1016/j.jaad.2025.10.086